InsidersTradesSigma
Follow the Metagenomi Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). The latest transaction was reported on 3 April 2026 (Attribution). Among the most active insiders: Wapnick Pamela. The full history is free.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
6 of 6 declarations
Metagenomi Therapeutics, Inc. is a biotechnology company focused on developing innovative gene therapies. It leverages advanced technologies to address genetic diseases and other medical conditions.